litlas
Log inCreate account

Lori J. Goldstein

Active 1989–2024

75
Papers
23,044
Citations
67
h-index
75
i10-index

Citations

Citations per year for Lori J. Goldstein1981: 1 citations1989: 9 citations1990: 31 citations1991: 44 citations1992: 41 citations1993: 41 citations1994: 25 citations1995: 32 citations1996: 40 citations1997: 26 citations1998: 24 citations1999: 22 citations2000: 29 citations2001: 35 citations2002: 40 citations2003: 75 citations2004: 70 citations2005: 92 citations2006: 118 citations2007: 103 citations2008: 129 citations2009: 154 citations2010: 160 citations2011: 146 citations2012: 140 citations2013: 116 citations2014: 156 citations2015: 189 citations2016: 162 citations2017: 169 citations2018: 153 citations2019: 533 citations2020: 603 citations2021: 589 citations2022: 518 citations2023: 415 citations2024: 711 citations2025: 249 citations2026: 16 citations1982–1988: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,515 citing papers, 28.1% of this breakdownChina: 982 citing papers, 11% of this breakdownItaly: 509 citing papers, 5.7% of this breakdownUnited Kingdom: 424 citing papers, 4.8% of this breakdownGermany: 397 citing papers, 4.4% of this breakdownCanada: 369 citing papers, 4.1% of this breakdownFrance: 295 citing papers, 3.3% of this breakdownAustralia: 232 citing papers, 2.6% of this breakdownSwitzerland: 232 citing papers, 2.6% of this breakdownNetherlands: 223 citing papers, 2.5% of this breakdownJapan: 217 citing papers, 2.4% of this breakdownSpain: 210 citing papers, 2.4% of this breakdown
0%28.1%Other 26.1%

Institutions

Fields

  • Medicine56.4%
  • Biochemistry, Genetics and Molecular Biology33.4%
  • Immunology and Microbiology2.8%
  • Computer Science2.4%
  • Engineering0.8%
  • Social Sciences0.7%
  • Other3.5%

Topics

  • Breast Cancer Treatment Studies10.5%
  • HER2/EGFR in Cancer Research4.1%
  • Cancer Immunotherapy and Biomarkers3.7%
  • Advanced Breast Cancer Therapies3.4%
  • Breast Lesions and Carcinomas3.2%
  • Cancer Treatment and Pharmacology2.5%
  • Other72.6%

Coauthors

All papers

Open in search
  1. Breast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology

    Authors: William J. Gradishar, Meena S. Moran, Jame Abraham, Rebecca Aft, Doreen M. Agnese, Kimberly H. Allison, Bethany Anderson, Harold J. Burstein, Helen K. Chew, Chau T. Dang, Anthony Elias, Sharon H. Giordano, Matthew P. Goetz, Lori J. Goldstein, Sara A. Hurvitz, Steven J. Isakoff, Rachel C. Jankowitz, Sara H. Javid, Jairam Krishnamurthy, Marilyn Leitch, Janice A. Lyons, Joanne Mortimer, Sameer A. Patel, Lori J. Pierce, Laura H. Rosenberger, Hope S. Rugo, Amy M. Sitapati, Karen L. Smith, Mary Lou Smith, Hatem Soliman, Erica Stringer-Reasor, Melinda L. Telli, John H. Ward, Kari B. Wisinski, Jessica Young, Jennifer L. Burns, Rashmi Kumar - Journal of the National Comprehensive Cancer Network 2022 cited by 964

  2. 21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer

    Authors: Kevin Kalinsky, William E. Barlow, Julie R. Gralow, Funda Meric-Bernstam, Kathy S. Albain, Daniel F. Hayes, Nancy U. Lin, Edith A. Perez, Lori J. Goldstein, Stephen K.L. Chia, Sukhbinder Dhesy-Thind, Priya Rastogi, Emilio Alba, Suzette Delaloge, Miguel Martin, Catherine M. Kelly, Manuel Ruiz-Borrego, Miguel Gil-Gil, Claudia H. Arce-Salinas, Etienne G.C. Brain, Eun-Sook Lee, Jean-Yves Pierga, Begoña Bermejo, Manuel Ramos-Vazquez, Kyung-Hae Jung, Jean-Marc Ferrero, Anne F. Schott, Steven Shak, Priyanka Sharma, Danika L. Lew, Jieling Miao, Debasish Tripathy, Lajos Pusztai, Gabriel N. Hortobagyi - New England Journal of Medicine 2021 cited by 832

  3. NCCN Guidelines® Insights: Breast Cancer, Version 4.2023

    Authors: William J. Gradishar, Meena S. Moran, Jame Abraham, Vandana G. Abramson, Rebecca Aft, Doreen M. Agnese, Kimberly H. Allison, Bethany Anderson, Harold J. Burstein, Helen K. Chew, Chau T. Dang, Anthony Elias, Sharon H. Giordano, Matthew P. Goetz, Lori J. Goldstein, Sara A. Hurvitz, Rachel C. Jankowitz, Sara H. Javid, Jairam Krishnamurthy, A. Marilyn Leitch, Janice A. Lyons, Joanne Mortimer, Sameer A. Patel, Lori J. Pierce, Laura H. Rosenberger, Hope S. Rugo, Bryan P. Schneider, Mary Lou Smith, Hatem Soliman, Erica Stringer-Reasor, Melinda L. Telli, Mei Wei, Kari B. Wisinski, Jessica Young, Kay T. Yeung, Mary A. Dwyer, Rashmi Kumar - Journal of the National Comprehensive Cancer Network 2023 cited by 440

  4. Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology

    Authors: William J. Gradishar, Benjamin O. Anderson, Jame Abraham, Rebecca Aft, Doreen M. Agnese, Kimberly H. Allison, Sarah L. Blair, Harold J. Burstein, Chau T. Dang, Anthony Elias, Sharon H. Giordano, Matthew P. Goetz, Lori J. Goldstein, Steven J. Isakoff, Jairam Krishnamurthy, Janice A. Lyons, P. Kelly Marcom, Jennifer M. Matro, Ingrid A. Mayer, Meena S. Moran, Joanne Mortimer, Ruth O’Regan, Sameer A. Patel, Lori J. Pierce, Hope S. Rugo, Amy M. Sitapati, Karen L. Smith, Mary Lou Smith, Hatem Soliman, Erica Stringer-Reasor, Melinda L. Telli, John H. Ward, Jessica Young, Jennifer L. Burns, Rashmi Kumar - Journal of the National Comprehensive Cancer Network 2020 cited by 1,618

  5. Prognostic Value of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancers From Two Phase III Randomized Adjuvant Breast Cancer Trials: ECOG 2197 and ECOG 1199

    Authors: Sylvia Adams, Robert J. Gray, Sandra Demaria, Lori J. Goldstein, Edith A. Perez, Lawrence N. Shulman, Silvana Martino, Molin Wang, Vicky Jones, Thomas J. Saphner, Antonio C. Wolff, William C. Wood, Nancy E. Davidson, George W. Sledge, Joseph A. Sparano, Sunil Badve - Journal of Clinical Oncology 2014 cited by 1,333

  6. Phase Ib Pilot Study to Evaluate Reparixin in Combination with Weekly Paclitaxel in Patients with HER-2–Negative Metastatic Breast Cancer

    Authors: Anne F. Schott, Lori J. Goldstein, Massimo Cristofanilli, Pier Adelchi Ruffini, Susan McCanna, James M. Reuben, Raymond P. Perez, Giraldo Kato, Max S. Wicha - Clinical Cancer Research 2017 cited by 240

  7. A window-of-opportunity trial of the CXCR1/2 inhibitor reparixin in operable HER-2-negative breast cancer

    Authors: Lori J. Goldstein, Raymond P. Perez, Denise A. Yardley, Linda K. Han, James M. Reuben, Hui Gao, Susan McCanna, Beth Butler, Pier Adelchi Ruffini, Yi Liu, Roberto R. Rosato, Jenny C. Chang - Breast Cancer Research 2020 cited by 137

  8. Cisplatin with veliparib or placebo in metastatic triple-negative breast cancer and BRCA mutation-associated breast cancer (S1416): a randomised, double-blind, placebo-controlled, phase 2 trial

    Authors: Eve T. Rodler, Priyanka Sharma, William E. Barlow, Julie R. Gralow, Shannon L. Puhalla, Carey K. Anders, Lori J. Goldstein, Debu Tripathy, Ursa Brown‐Glaberman, Thu-Tam Huynh, Christopher S Szyarto, Andrew K. Godwin, Harsh B. Pathak, Elizabeth M. Swisher, Marc R. Radke, Kirsten M. Timms, Danika L. Lew, Jieling Miao, Lajos Pusztai, Daniel F. Hayes, Gabriel N. Hortobágyi - The Lancet Oncology 2023 cited by 98

  9. Randomized Phase II Trial of Fulvestrant Plus Everolimus or Placebo in Postmenopausal Women With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy: Results of PrE0102

    Authors: Noah Kornblum, Fengmin Zhao, Judith Manola, Paula Klein, Bhuvaneswari Ramaswamy, Adam Brufsky, Phillip J. Stella, Brian L. Burnette, Melinda L. Telli, Della Makower, P. Cheema, Cristina I. Truica, Antonio C. Wolff, Gamini S. Soori, Barbara Haley, Timothy R. Wassenaar, Lori J. Goldstein, Kathy D. Miller, Joseph A. Sparano - Journal of Clinical Oncology 2018 cited by 189

  10. NCCN Guidelines Insights: Breast Cancer, Version 1.2017

    Authors: William J. Gradishar, Benjamin O. Anderson, Ronald Balassanian, Sarah L. Blair, Harold J. Burstein, Amy Cyr, Anthony Elias, William B. Farrar, Andres Forero, Sharon H. Giordano, Matthew P. Goetz, Lori J. Goldstein, Steven J. Isakoff, Janice A. Lyons, P. Kelly Marcom, Ingrid A. Mayer, Beryl McCormick, Meena S. Moran, Ruth O’Regan, Sameer A. Patel, Lori J. Pierce, Elizabeth Reed, Kilian Salerno, Lee S. Schwartzberg, Amy M. Sitapati, Karen L. Smith, Mary Lou Smith, Hatem Soliman, George Somlo, Melinda L. Telli, John H. Ward, Dorothy A. Shead, Rashmi Kumar - Journal of the National Comprehensive Cancer Network 2017 cited by 542

  11. NCCN Guidelines® Insights: Breast Cancer, Version 4.2021

    Authors: William J. Gradishar, Meena S. Moran, Jame Abraham, Rebecca Aft, Doreen M. Agnese, Kimberly H. Allison, Sarah L. Blair, Harold J. Burstein, Chau T. Dang, Anthony Elias, Sharon H. Giordano, Matthew P. Goetz, Lori J. Goldstein, Sara A. Hurvitz, Steven J. Isakoff, Rachel C. Jankowitz, Sara H. Javid, Jairam Krishnamurthy, Marilyn Leitch, Janice A. Lyons, Jennifer M. Matro, Ingrid A. Mayer, Joanne Mortimer, Ruth O’Regan, Sameer A. Patel, Lori J. Pierce, Hope S. Rugo, Amy M. Sitapati, Karen L. Smith, Mary Lou Smith, Hatem Soliman, Erica Stringer-Reasor, Melinda L. Telli, John H. Ward, Kari B. Wisinski, Jessica Young, Jennifer L. Burns, Rashmi Kumar - Journal of the National Comprehensive Cancer Network 2021 cited by 351

  12. A randomized, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for metastatic triple-negative breast cancer (fRida)

    Authors: Lori J. Goldstein, Mauro Mansutti, Christelle Lévy, Jenny C. Chang, Stéphanie Henry, I. Fernández-Pérez, Jana Prausová, Elżbieta Starosławska, Giuseppe Viale, Beth Butler, Susan McCanna, Pier Adelchi Ruffini, Max S. Wicha, Anne F. Schott, for the fRida Trial Investigators, Ricardo H. Álvarez, Anne F. Schott, Maysa Abu‐Khalaf, Nuhad Ibrahim, Brooke Daniel, Michael W. Meshad, David E. Kanamori, Amelia Zelnak, Mark S. Graham, Jason E. Comer, Manon Huizing, François Duhoux, Vincent R. Richard, Didier Verhoeven, Martin Šmakal, Marta Krásenská, Milan Kohoutek, Martina Zimovjanová, Eugen Kubala, Mario Campone, Jean-­Marc Ferrero, Anthony Gonçalvès, Laurence Venat‐Bouvet, Jacques Médioni, Laura Biganzoli, Héctor Soto Parrà, Paolo Pedrazzoli, Marco Colleoni, Mauro Moroni, Dino Amadori, Paolo Morandi, Saverio Cinieri, Piotr Tomczak, Tomasz Sarosiek, Marek Z. Wojtukiewicz, Andrzej Mruk, Bożena Kukiełka-Budny, Silvia Antolin Novoa, Estela Vega Alonso, M. Martín Jiménez - Breast Cancer Research and Treatment 2021 cited by 101

  13. Goserelin for Ovarian Protection during Breast-Cancer Adjuvant Chemotherapy

    Authors: Halle C. F. Moore, Joseph M. Unger, Kelly‐Anne Phillips, Frances Boyle, Erika Hitre, David Porter, Prudence A. Francis, Lori J. Goldstein, Henry Gómez, Carlos Vallejos, Ann H. Partridge, Shaker R. Dakhil, Agustin A. García, Julie R. Gralow, Janine Lombard, John Forbes, Silvana Martino, William E. Barlow, Carol J. Fabian, Lori M. Minasian, Frank L. Meyskens, Richard D. Gelber, Gabriel N. Hortobágyi, Kathy S. Albain - New England Journal of Medicine 2015 cited by 542

  14. Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology

    Authors: William J. Gradishar, Benjamin O. Anderson, Ronald Balassanian, Sarah L. Blair, Harold J. Burstein, Amy Cyr, Anthony Elias, William B. Farrar, Andres Forero, Sharon H. Giordano, Matthew P. Goetz, Lori J. Goldstein, Steven J. Isakoff, Janice A. Lyons, P. Kelly Marcom, Ingrid A. Mayer, Beryl McCormick, Meena S. Moran, Ruth O’Regan, Sameer A. Patel, Lori J. Pierce, Elizabeth Reed, Kilian Salerno, Lee S. Schwartzberg, Amy M. Sitapati, Karen L. Smith, Mary Lou Smith, Hatem Soliman, George Somlo, Melinda L. Telli, John H. Ward, Rashmi Kumar, Dorothy A. Shead - Journal of the National Comprehensive Cancer Network 2018 cited by 1,616

  15. Early Local Therapy for the Primary Site in De Novo Stage IV Breast Cancer: Results of a Randomized Clinical Trial (E2108)

    Authors: Seema A. Khan, Fengmin Zhao, Lori J. Goldstein, David Cella, Mark Basik, Mehra Golshan, Thomas B. Julian, Barbara A. Pockaj, Christine A. Lee, Wajeeha Razaq, Joseph A. Sparano, Gildy V. Babiera, Irene A. Dy, Sarika Jain, Paula Silverman, Carla S. Fisher, Amye J. Tevaarwerk, Lynne I. Wagner, George W. Sledge - Journal of Clinical Oncology 2022 cited by 178

  16. Computational pathology improves risk stratification of a multi-gene assay for early stage ER+ breast cancer

    Authors: Yuli Chen, Haojia Li, Andrew Janowczyk, Paula Toro, Germán Corredor, Jon Whitney, Cheng Lu, Can Koyuncu, Mojgan Mokhtari, Christina Buzzy, Shridar Ganesan, Michael D. Feldman, Pingfu Fu, Haley Corbin, Aparna Harbhajanka, Hannah Gilmore, Lori J. Goldstein, Nancy E. Davidson, Sangeeta Desai, Vani Parmar, Anant Madabhushi - npj Breast Cancer 2023 cited by 28

  17. Dasatinib as a Single Agent in Triple-Negative Breast Cancer: Results of an Open-Label Phase 2 Study

    Authors: Richard S. Finn, Carmelo Bengala, Nuhad K. Ibrahim, Henri Roché, Joseph A. Sparano, Lewis C. Strauss, Justin Fairchild, Oumar Sy, Lori J. Goldstein - Clinical Cancer Research 2011 cited by 216

  18. Survival in patients with metastatic recurrent breast cancer after adjuvant chemotherapy

    Authors: Amyé Tevaarwerk, Robert J. Gray, Bryan P. Schneider, Mary Lou Smith, Lynne I. Wagner, John H. Fetting, Nancy E. Davidson, Lori J. Goldstein, Kathy D. Miller, Joseph A. Sparano - Cancer 2012 cited by 193

  19. Collagen fiber orientation disorder from H&E images is prognostic for early stage breast cancer: clinical trial validation

    Authors: Haojia Li, Kaustav Bera, Paula Toro, Pingfu Fu, Zelin Zhang, Cheng Lu, Michael D. Feldman, Shridar Ganesan, Lori J. Goldstein, Nancy E. Davidson, Akisha Glasgow, Aparna Harbhajanka, Hannah Gilmore, Anant Madabhushi - npj Breast Cancer 2021 cited by 55

  20. Systemic Therapies Following Progression on First-line CDK4/6-inhibitor Treatment: Analysis of Real-world Data

    Authors: James Martin, Elizabeth A. Handorf, Alberto J. Montero, Lori J. Goldstein - The Oncologist 2022 cited by 56

  21. Niraparib for Advanced Breast Cancer with Germline BRCA1 and BRCA2 Mutations: the EORTC 1307-BCG/BIG5–13/TESARO PR-30–50–10-C BRAVO Study

    Authors: Nicholas C. Turner, Judith Balmañà, Coralie Poncet, Theodora Goulioti, Konstantinos Tryfonidis, Aafke H. Honkoop, Gabriele Zoppoli, Evangelia Razis, Óskar Þór Jóhannsson, Marco Colleoni, Andrew Tutt, William Audeh, Michail Ignatiadis, Audrey Mailliez, Olivier Trédan, Antonino Musolino, Peter Vuylsteke, María José Juan-Fita, Iain R. Macpherson, Bella Kaufman, Luís Manso, Lori J. Goldstein, Susan Ellard, István Láng, Kai Yu Jen, Virginie Adam, Saskia Litière, John K. Erban, David Cameron - Clinical Cancer Research 2021 cited by 52

  22. Improved Outcomes From Adding Sequential Paclitaxel but Not From Escalating Doxorubicin Dose in an Adjuvant Chemotherapy Regimen for Patients With Node-Positive Primary Breast Cancer

    Authors: I. Craig Henderson, Donald A. Berry, George D. Demetri, Constance Cirrincione, Lori J. Goldstein, Silvana Martino, James N. Ingle, M. Robert Cooper, Daniel F. Hayes, Katherine H. R. Tkaczuk, Gini F. Fleming, James F. Holland, David B. Duggan, John T. Carpenter, Emil Frei, Richard L. Schilsky, William C. Wood, Hyman B. Muss, Larry Norton - Journal of Clinical Oncology 2003 cited by 1,302

  23. Breast Cancer, Version 3.2018

    Authors: Matthew P. Goetz, William J. Gradishar, Benjamin O. Anderson, Jame Abraham, Rebecca Aft, Kimberly H. Allison, Sarah L. Blair, Harold J. Burstein, Chau T. Dang, Anthony Elias, William B. Farrar, Sharon H. Giordano, Lori J. Goldstein, Steven J. Isakoff, Janice A. Lyons, P. Kelly Marcom, Ingrid A. Mayer, Meena S. Moran, Joanne Mortimer, Ruth M. O'Regan, Sameer A. Patel, Lori J. Pierce, Elizabeth Reed, Hope S. Rugo, Amy M. Sitapati, Karen L. Smith, Mary Lou Smith, Hatem Soliman, Melinda L. Telli, John H. Ward, Jessica Young, Dorothy A. Shead, Rashmi Kumar - Journal of the National Comprehensive Cancer Network 2019 cited by 199

  24. Cancer‐related relationship communication in couples coping with early stage breast cancer

    Authors: Sharon L. Manne, Jamie S. Ostroff, Tina R. Norton, Kevin R. Fox, Lori J. Goldstein, Generosa Grana - Psycho-Oncology 2005 cited by 307